# Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients

> **NCT04155918** · PHASE2 · COMPLETED · sponsor: **Arthrosi Therapeutics** · enrollment: 30 (actual)

## Conditions studied

- Gout Patients

## Interventions

- **DRUG:** Group 1: AR882 Alone and in Combination with Febuxostat (FBX)
- **DRUG:** Group 2: AR882 Alone and in Combination with Allopurinol (ALLO)

## Key facts

- **NCT ID:** NCT04155918
- **Lead sponsor:** Arthrosi Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-03
- **Primary completion:** 2020-09-03
- **Final completion:** 2020-09-03
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04155918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04155918, "Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04155918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*